Themis Medicare Launches Lenzetto®

As life span of women is increasing in India, post-menopausal health status assumes increasing importance in Women's Healthcare. Most post-menopausal women remain unaware of the short and long-term implications of menopause due to lack of recognition of menopausal symptoms and unavailability of safe and convenient treatment options. Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai with a legacy of over 50 years of making new treatment options available, announced the launch of a novel transdermal Estradiol spray Lenzetto® in the Indian market for treatment of Menopausal Symptoms.

Lenzetto® has a clinical experience in 40 countries and is approved by USFDA & EMA for the treatment of Menopausal Symptoms. Lenzetto® is manufactured in Europe by Gedeon Richter, The Global Innovators in Women's Health. Lenzetto® a novel transdermal estradiol with Metered Dose Transdermal Spray (MDTS) Technology) delivers therapeutic doses of estradiol to the skin, using a metering pump containing 1.53 mg/spray estradiol hemihydrate. Transdermal delivery of estrogen is well established in clinical practice and ensures sufficient serum estradiol levels to alleviate Menopausal Symptoms like hot flashes, night sweats etc. at lower overall estradiol exposure while avoiding some of the consequences of high hepatic exposure and first-pass metabolism.

Clinical studies have shown that estradiol delivered in Lenzetto®1.53 mg/spray transdermal spray formulation is absorbed through the skin and provides steady serum concentrations throughout 24 hrs. for the treatment of menopausal symptoms in peri-menopausal and postmenopausal women.

Various studies suggest that 1.53 mg estradiol transdermal spray is a valuable HRT option, demonstrating high acceptability and satisfaction amongst menopausal women, which enhances adherence to treatment. Guidelines from various Menopause Societies around the world like British Menopause Society, International Menopause Society and North American Menopause Society recommend Transdermal as a preferred route for Estradiol for treatment of Menopausal Symptoms.

Lenzetto® would be available on prescription.

Based on the product's benefit, Lenzetto® appears to offer another therapeutic option to Gynecologists for treating Menopausal symptoms in women with immense clinical benefit.

Speaking at the release, Dr. Sachin Patel, Managing Director& CEO of Themis Medicare Ltd. said, "Our endeavor has always been to provide world class medicines that benefit patients and make healthcare far, far more effective. Given the fact that Gynecologists currently have limited treatment options for menopausal women, Lenzetto®appears to offer a much needed therapeutic option to Gynecologists for treating Menopausal symptoms in women with immense clinical benefit and Convenience. Lenzetto® will provide Convenience to women as it is transdermal spray that Menopausal women can just "Spray and Go" unlike currently available transdermal Gel which are inconvenient and messy to apply. Lenzetto® will be promoted by a task force which will be exclusively meeting Gynecologists across the country."

According to Themis Medicare Limited, Lenzetto® is manufactured in and imported from Gedeon Richter, Hungary. Lenzetto® and will be available in a Transdermal Spray that facilitates "Metered Dose Application" on to Small Skin Surface Area in a unique easy to use packaging.

With a strong R&D backup, skilled domestic & export teams, and state-of-the-art manufacturing sites, the endeavour at Themis has always been to support the medical fraternity with solutions for major unmet medical needs and Lenzetto®launch is yet another step in this direction.

Shares of Themis Medicare Limited was last trading in BSE at Rs. 1349.40 as compared to the previous close of Rs. 1401.10. The total number of shares traded during the day was 2164 in over 470 trades.

The stock hit an intraday high of Rs. 1400.50 and intraday low of 1330.00. The net turnover during the day was Rs. 2959589.00.

Source : Equity Bulls

Keywords

ThemisMedicare INE083B01016 Pharmaceuticals Lenzetto MenopausalSymptoms Treatment